tolvaptan has been researched along with Lung Diseases in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eguchi, A; Hirotani, S; Iwasaku, T; Mano, T; Masuyama, T; Naito, Y; Okuhara, Y | 1 |
1 other study(ies) available for tolvaptan and Lung Diseases
| Article | Year |
|---|---|
Long-term administration of tolvaptan increases myocardial remodeling and mortality via exacerbation of congestion in mice heart failure model after myocardial infarction.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Models, Animal; Heart Failure; Lung Diseases; Male; Mice; Mice, Inbred C57BL; Mortality; Myocardial Infarction; Random Allocation; Time Factors; Tolvaptan; Ventricular Remodeling | 2016 |